Biotechnology company developing next-generation proteasome inhibitors for oncology, hematology, and immunology
Biotechnology company developing next-generation proteasome inhibitors for oncology, hematology, and immunology. Its structure-based inhibitor platform is also being advanced as a broad-spectrum antibody-drug conjugate (ADC) payload platform.